CreatorsPublishersAdvertisers
View more in
San Francisco, CA

Dr. Martin on the Utility of Quadruplet-Based Regimens in Relapsed/Refractory Multiple Myeloma

onclive.com
 2021-09-10

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma. Thomas G. Martin, MD, director of clinical research, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

www.onclive.com

Comments / 0

Comments / 0